$TRXC 1.33 Upgraded. Transenterix Inc (NASDAQ:TRXC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States. “
Shares of Transenterix (NASDAQ:TRXC) traded down 1.56% on Tuesday, reaching $1.26. 101,140 shares of the company were exchanged. The company’s 50-day moving average is $1.39 and its 200-day moving average is $2.69. Transenterix has a 52 week low of $1.03 and a 52 week high of $6.10. The company’s market capitalization is $144.62 million.
In other Transenterix news, CTO Anthony C. J. Fernando purchased 27,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 14th. The shares were bought at an average price of $1.46 per share, with a total value of $39,420.00. Following the completion of the purchase, the chief technology officer now directly owns 27,000 shares in the company, valued at $39,420. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.